Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Terkenli
Page 1
Training Excitatory-Inhibitory Recurrent Neural Networks for Cognitive Tasks: A Simple and Flexible Framework.
Song HF, Yang GR, Wang XJ. Song HF, et al. PLoS Comput Biol. 2016 Feb 29;12(2):e1004792. doi: 10.1371/journal.pcbi.1004792. eCollection 2016 Feb. PLoS Comput Biol. 2016. PMID: 26928718 Free PMC article.
However, existing RNNs lack basic biological features such as the distinction between excitatory and inhibitory units (Dale's principle), which are essential if RNNs are to provide insights into the operation of biological circuits. ...We provide an implementation based on …
However, existing RNNs lack basic biological features such as the distinction between excitatory and inhibitory units (Dale's princip …
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
Terpos E, Gavriatopoulou M, Fotiou D, Giatra C, Asimakopoulos I, Dimou M, Sklirou AD, Ntanasis-Stathopoulos I, Darmani I, Briasoulis A, Kastritis E, Angelopoulou M, Baltadakis I, Panayiotidis P, Trougakos IP, Vassilakopoulos TP, Pagoni M, Dimopoulos MA. Terpos E, et al. Cancers (Basel). 2021 Sep 6;13(17):4480. doi: 10.3390/cancers13174480. Cancers (Basel). 2021. PMID: 34503290 Free PMC article.
We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma (HL). An FDA-approved, ELISA-based methodology was implemented to evaluate the titers of neutra …
We evaluated the humoral response following the BNT162b2 vaccine in patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's l …